TACI-immunoglobulin fusion proteins
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
1. A fusion protein comprising
(a) a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residues 30 to 154 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) an immunoglobulin moiety that comprises a C H2 and a C H3 domain.
2. The fusion protein of claim 1 , wherein the immunoglobulin moiety is an IgGl Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
3. A fusion protein, comprising:
(a) a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residues 30 to 110 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) an immunoglobulin moiety that comprises a C H2 and a C H3 domain.
4. The fusion protein of claim 3 , wherein the immunoglobulin moiety is an IgG1 Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
5. The fusion protein of claim 3 , wherein the encoded fusion protein has an amino acid sequence comprising the secreted form of the amino acid sequence of SEQ ID NO:54.
6. The fusion protein of claim 3 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:54, wherein the optimized tPA (otPA) leader sequence (SEQ ID NO:25) has been removed.
7. A pharmaceutical composition comprising a fusion protein, comprising:
(a) a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residue 30 to 154 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) an immunoglobulin moiety that comprises a C H2 and a C H3 domain.
8. The pharmaceutical composition of claim 7 , wherein the immunoglobulin moiety is an IgG1 immunoglobulin moiety.
9. The pharmaceutical composition of claim 7 , wherein the immunoglobulin moiety is an IgG1 Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
10. A pharmaceutical composition comprising a fusion protein, comprising:
(a) a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residues 30 to 110 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) an immunoglobulin moiety that comprises a C H2 and a C H3 domain.
11. The pharmaceutical composition of claim 10 , wherein the immunoglobulin moiety is an IgG1 immunoglobulin moiety.
12. The pharmaceutical composition of claim 10 , wherein the immunoglobulin moiety is an IgG1 Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
13. The pharmaceutical composition of claim 10 , wherein the encoded fusion protein has an amino acid sequence comprising the secreted form of the amino acid sequence of SEQ ID NO:54.
14. The pharmaceutical composition of claim 10 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 54, wherein the optimized tPA (otPA) leader sequence (SEQ ID NO:25) has been removed.